Literature DB >> 28057737

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).

Cyrille Touzeau1,2, Steven Le Gouill1,2, Béatrice Mahé1, Jean Samuel Boudreault1, Thomas Gastinne1, Nicolas Blin1, Hélène Caillon3, Christelle Dousset1,2, Martine Amiot1,2, Philippe Moreau4,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28057737      PMCID： PMC5394947          DOI： 10.3324/haematol.2016.160408

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Authors:  Jesus San Miguel; Katja Weisel; Philippe Moreau; Martha Lacy; Kevin Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Anne Banos; Albert Oriol; Adrian Alegre; Christine Chen; Michele Cavo; Laurent Garderet; Valentina Ivanova; Joaquin Martinez-Lopez; Andrew Belch; Antonio Palumbo; Stephen Schey; Pieter Sonneveld; Xin Yu; Lars Sternas; Christian Jacques; Mohamed Zaki; Meletios Dimopoulos
Journal:  Lancet Oncol       Date:  2013-09-03       Impact factor: 41.316

2.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

3.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Authors:  S K Kumar; J H Lee; J J Lahuerta; G Morgan; P G Richardson; J Crowley; J Haessler; J Feather; A Hoering; P Moreau; X LeLeu; C Hulin; S K Klein; P Sonneveld; D Siegel; J Bladé; H Goldschmidt; S Jagannath; J S Miguel; R Orlowski; A Palumbo; O Sezer; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2011-07-29       Impact factor: 11.528

4.  Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Authors:  Sagar Lonial; Brendan M Weiss; Saad Z Usmani; Seema Singhal; Ajai Chari; Nizar J Bahlis; Andrew Belch; Amrita Krishnan; Robert A Vescio; Maria Victoria Mateos; Amitabha Mazumder; Robert Z Orlowski; Heather J Sutherland; Joan Bladé; Emma C Scott; Albert Oriol; Jesus Berdeja; Mecide Gharibo; Don A Stevens; Richard LeBlanc; Michael Sebag; Natalie Callander; Andrzej Jakubowiak; Darrell White; Javier de la Rubia; Paul G Richardson; Steen Lisby; Huaibao Feng; Clarissa M Uhlar; Imran Khan; Tahamtan Ahmadi; Peter M Voorhees
Journal:  Lancet       Date:  2016-01-07       Impact factor: 79.321

5.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

6.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

Review 7.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

8.  BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.

Authors:  C Touzeau; J Ryan; J Guerriero; P Moreau; T N Chonghaile; S Le Gouill; P Richardson; K Anderson; M Amiot; A Letai
Journal:  Leukemia       Date:  2015-07-15       Impact factor: 11.528

9.  The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.

Authors:  C Touzeau; C Dousset; S Le Gouill; D Sampath; J D Leverson; A J Souers; S Maïga; M C Béné; P Moreau; C Pellat-Deceunynck; M Amiot
Journal:  Leukemia       Date:  2013-07-17       Impact factor: 11.528

10.  Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.

Authors:  S M Matulis; V A Gupta; A K Nooka; H V Hollen; J L Kaufman; S Lonial; L H Boise
Journal:  Leukemia       Date:  2015-12-28       Impact factor: 11.528
View more
  7 in total

Review 1.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Authors:  Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai
Journal:  Cancer Discov       Date:  2017-11-16       Impact factor: 39.397

2.  Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone.

Authors:  Nelson Leung; Stephan D Thomé; Angela Dispenzieri
Journal:  Haematologica       Date:  2018-01-19       Impact factor: 9.941

3.  The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Authors:  Nelson Leung; Frank Bridoux; Vecihi Batuman; Aristeidis Chaidos; Paul Cockwell; Vivette D D'Agati; Angela Dispenzieri; Fernando C Fervenza; Jean-Paul Fermand; Simon Gibbs; Julian D Gillmore; Guillermo A Herrera; Arnaud Jaccard; Dragan Jevremovic; Efstathios Kastritis; Vishal Kukreti; Robert A Kyle; Helen J Lachmann; Christopher P Larsen; Heinz Ludwig; Glen S Markowitz; Giampaolo Merlini; Peter Mollee; Maria M Picken; Vincent S Rajkumar; Virginie Royal; Paul W Sanders; Sanjeev Sethi; Christopher P Venner; Peter M Voorhees; Ashutosh D Wechalekar; Brendan M Weiss; Samih H Nasr
Journal:  Nat Rev Nephrol       Date:  2019-01       Impact factor: 28.314

4.  [Efficacy and safety analysis of BCL-2 inhibitor in relapsed/refractory multiple myeloma with t (11;14) in a single center].

Authors:  J Y Bi; L Wen; W B Duan; Y Liu; S S Wang; X J Huang; J Lu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-02-14

5.  Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.

Authors:  Cameron S Fraser; Johan K E Spetz; Xingping Qin; Adam Presser; Jonathan Choiniere; Chendi Li; Stacey Yu; Frances Blevins; Aaron N Hata; Jeffrey W Miller; Gary A Bradshaw; Marian Kalocsay; Vaishali Sanchorawala; Shayna Sarosiek; Kristopher A Sarosiek
Journal:  Nat Commun       Date:  2022-10-02       Impact factor: 17.694

Review 6.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20

7.  Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.

Authors:  Carolane Seiller; Sophie Maiga; Cyrille Touzeau; Céline Bellanger; Charlotte Kervoëlen; Géraldine Descamps; Laurent Maillet; Philippe Moreau; Catherine Pellat-Deceunynck; Patricia Gomez-Bougie; Martine Amiot
Journal:  Cell Death Dis       Date:  2020-05-05       Impact factor: 8.469
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.